While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Regulators, policymakers and others can more effectively battle the disease by creating incentives to make mpox a more ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

BioNTech (NASDAQ:BNTX) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

Cancer Vaccines Market revenue is expected to hold around USD 24.22 billion by 2033 from USD 9 million in 2023 with a ...

The FDA issued Emergency Use Authorization for the Pfizer-BioNTech vaccine on Dec. 11, 2020, and for the Moderna vaccine on Dec. 18, 2020 for those 18 and older. Novavax was approved June 7, 2022 ...

BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.

Scientists have discovered a new species of ghost shark that lives in deep ocean waters near Australia and New Zealand.

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...